Watch LIVE the focusIR May Investor webinar with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNuformix Share News (NFX)

Share Price Information for Nuformix (NFX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.185
Bid: 0.17
Ask: 0.20
Change: 0.00 (0.00%)
Spread: 0.03 (17.647%)
Open: 0.185
High: 0.00
Low: 0.00
Prev. Close: 0.185
NFX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Nuformix says NXP002 shows anti-inflammatory effect

Thu, 18th May 2023 14:31

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Sareum Holdings PLC - Cambridge-based biotechnology company developing kinase inhibitors for autoimmune diseases and cancers - Commences a phase 1a clinical trial for its SDC-1801 treatment. Says patient recruitment is in progress at clinical units in Victoria, Australia. SDC-1801 is a potential therapeutic for a number of autoimmune diseases. Says application trial follows approval by the Human Research Ethics Committee, while the application has also been acknowledged by Australia's Therapeutic Goods Administration. Says phase 1b clinical study expected to begin in psoriasis patients in 2024.

----------

Nuformix PLC - London-based pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing - Says study data indicates its NXP002 treatment alone delivers an anti-inflammatory effect, suppressing the release of inflammatory cytokines by over 90%. Adds that the treatment shows an addition anti-inflammatory effect when used with current standards of care. Says results suggest NXP002 increases efficacy of existing therapies with the benefit of inhaled delivery. Says anti-inflammatory takes only an hour to have an effect, and strong effect lasts for 12 hours, and anti-inflammatory effect is still present after 24 hours. "I'm absolutely delighted with the data we've generated over recent months - all the results we've achieved are as good as we could have hoped for and are the first results from advanced 'close to patient' IPF and inflammation human tissue disease models," comments Executive director Dan Gooding.

----------

Conygar Investment Co PLC - London-based property investor and developer - Says Nottingham City Council has approved its application for the next phase of The Island Quarter development. Says application includes 23,123 square metre bioscience building, including laboratory and office space. Chief Executive Robert Ware comments: "We are delighted that the next phase of development has been approved. Nottingham is already home to a large number of exciting businesses in the bioscience space and this scheme will be an excellent addition to the mixed-use development we are creating at The Island Quarter".

----------

Secure Trust Bank PLC - Solihull, England-based savings accounts and lending services provider - Says net lending in the first quarter of 2023 was GBP3.01 billion, up 17% from GBP2.57 billion a year ago. New business lending rose 7.2% to GBP523.5 million, from GBP488.2 million, which it says demonstrates sustained growth momentum, in spite of tightened lending criteria. Adds that its cost optimisation programme is on track to deliver GBP4 million in annualised savings by the end of 2023. "We see significant opportunity for sustainable growth in our focused market segments and are well positioned to help consumers and businesses fulfil their ambitions and to continue to grow our net lending and scale our business as we strengthen our distribution networks and relationships...Although the economic environment remains uncertain, we have started the year positively and are confident in delivering on our plans for the full year and our medium term targets," Chief Executive David McCreadie says.

----------

Artemis Resources Ltd - Perth-based based mining company, with gold, copper and cobalt projects in Australia - Says historical geology and a data review confirms that its 2020 drill programme intercepted gold mineralisation within a quartz diorite intrusion. Says drilling has defined the intrusion over 2 kilometres, with elevated gold in rock chips over a strike length of 4 kilometres. Says there may be a possible relationship with Sanukitoid granitoids identified by De Grey Mining in the Mallina basin. Adds that an induced polarisation survey will begin in May, in order to help identify sulphides at depth. Exploration Manager Luke Meter says: "We have a new understanding of the importance of intrusion related gold in the Pilbara, including the identification of Sanukitoid like intrusions by the GSWA in the vicinity of the Karratha Granodiorite, some 2.5 km from Lulu Creek. The significance of the historic gold mineralisation therefore becomes apparent. With the Lulu Creek reconnaissance drill holes displaying similar grade and scale to De Grey's Diucon deposits, the potential upside for Lulu Creek is appreciable."

----------

By Harvey Dorset, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
28 Jul 2022 16:14

EXECUTIVE CHANGES: Cohort co-founder out; Nuformix co-founder back

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Thursday and not separately reported by Alliance News:

Read more
28 Jul 2022 15:01

EARNINGS UPDATES: Alliance Trust beats benchmark and ups dividend

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
29 Jun 2022 12:25

IN BRIEF: Nuformix shares rise as progresses with cancer programme

Nuformix PLC - London-based pharmaceutical development firm focused on fibrosis and oncology via drug repurposing - Starts to scale-up the production processes of lead cocrystals for its cancer programme NXP004, focused on the treatment for advanced ovarian cancer. Firm aims to develop new forms of Olaparib, "currently marketed by AstraZeneca PLC, under the Lynparza brand name," Nuformix explains. First approved in 2014 for advanced ovarian cancer, it has since received "similar approvals in breast, pancreatic and prostate cancers with further trials on-going."

Read more
27 Jun 2022 21:51

TRADING UPDATES: Anglo-Eastern Plantations sees palm oil prices rise

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
31 May 2022 12:41

Nuformix Executive Chair Alastair Riddell resigns after one year

(Alliance News) - Nuformix PLC on Tuesday said Executive Chair Alastair Riddell has resigned with immediate effect.

Read more
30 May 2022 11:54

IN BRIEF: Nuformix shares plunge on inconsistent repeat study results

Nuformix PLC - London-based pharmaceutical development firm focused on fibrosis and oncology via drug repurposing - Says the contract research organisation undertaking the final planned pre-clinical study for its NXP002 treatment had a protocol failure, which has voided the study. Says the organisation repeated the study and recorded results that were inconsistent with the first in vivo study at all time points and also with the oral control. Notes that no positive or negative conclusions could be drawn from this study.

Read more
30 May 2022 11:13

SMALL-CAP WINNERS & LOSERS: Foxtons finds new CEO; S4 revenue surges

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Monday.

Read more
28 Mar 2022 19:18

IN BRIEF: Nuformix NXP004 patent application reaches publication phase

Nuformix PLC - London-based pharmaceutical development firm focused on fibrosis and oncology via drug repurposing - Says patent application for key asset NXP004 had progressed to the publication phase. NXP004 is a new formulation of Olaparib, which is used to treat ovarian, breast and pancreatic cancers currently marketed by FTSE 100-listed AstraZeneca PLC, under the name Lynparza. The patent application, which was made in September 2020, covers new olaparib oxalic acid cocrystals, their therapeutic uses and pharmaceutical compositions containing them. A second patent application was filed last November which remains pending.

Read more
8 Feb 2022 13:58

TRADING UPDATES: Round Hill Music buys Alice In Chains catalogue

TRADING UPDATES: Round Hill Music buys Alice In Chains catalogue

Read more
8 Feb 2022 10:52

SMALL-CAP WINNERS & LOSERS: Nuformix jumps as partner inks contract

SMALL-CAP WINNERS & LOSERS: Nuformix jumps as partner inks contract

Read more
14 Dec 2021 18:01

TRADING UPDATES: Cohort interim loss widens, Yourgene loss narrows

TRADING UPDATES: Cohort interim loss widens, Yourgene loss narrows

Read more
25 Nov 2021 16:23

IN BRIEF: Nuformix notes positive results for inhaled NXP002 dose

IN BRIEF: Nuformix notes positive results for inhaled NXP002 dose

Read more
12 Nov 2021 12:11

TRADING UPDATES: Princess exits Taco Bell; Nuformix files patent

TRADING UPDATES: Princess exits Taco Bell; Nuformix files patent

Read more
12 Nov 2021 10:54

SMALL-CAP WINNERS & LOSERS: Avon Protection plates face approval delay

SMALL-CAP WINNERS & LOSERS: Avon Protection plates face approval delay

Read more
9 Nov 2021 15:30

CORRECT: Nuformix Chair Alastair Riddell to move to executive chair

CORRECT: Nuformix Chair Alastair Riddell to move to executive chair

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.